Next generation proteomics with drug sensitivity screening identifies sub-clones informing therapeutic and drug development strategies for multiple myeloma patients

Next generation proteomics with drug sensitivity screening identifies sub-clones informing therapeutic and drug development strategies for multiple myeloma patients

Abstract With the introduction of novel therapeutic agents, survival in Multiple Myeloma (MM) has increased in recent years. However, drug-resistant clones inevitably arise and lead to disease progression and death. The current International Myeloma Working Group response criteria are broad and make...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ciara Tierney, Despina Bazou, Muntasir M. Majumder, Pekka Anttila, Raija Silvennoinen, Caroline A. Heckman, Paul Dowling, Peter O’Gorman
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/108cd3dd8b6c4ba986fd1fc4eda995a5
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares